Form 8-K - Current report:
SEC Accession No. 0001815776-24-000058
Filing Date
2024-08-14
Accepted
2024-08-14 16:08:15
Documents
15
Period of Report
2024-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20240814.htm   iXBRL 8-K 27580
2 EX-99.1 a991q224pressrelease.htm EX-99.1 66901
6 image_0a.jpg GRAPHIC 28536
  Complete submission text file 0001815776-24-000058.txt   272319

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20240814.xsd EX-101.SCH 1889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20240814_lab.xml EX-101.LAB 23433
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20240814_pre.xml EX-101.PRE 13570
18 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20240814_htm.xml XML 3041
Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 241207665
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)